An Adjusted Calculation Model Allows for Reduced Protamine Doses without Increasing Blood Loss in Cardiac Surgery

Thoracic and Cardiovascular Surgeon

Volumn 64, Issue 6, 2016, Pages 487-493

  Kjellberg, Gunilla ^a   Sartipy, Ulrik ^b   Van Der Linden, Jan ^b   Nissborg, Emelie ^b   Lindvall, Gabriella ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

blood; cardiopulmonary bypass; coagulation anticoagulation; CPB; perfusion

Indexed keywords

HEMOGLOBIN; HEPARIN; PROTAMINE; ANTICOAGULANT AGENT; HEPARIN ANTAGONIST;

ADULT; AGED; ANTICOAGULANT THERAPY; AORTA VALVE REPLACEMENT; ARTICLE; BLOOD CLOTTING TIME; BODY WEIGHT; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG DOSE REDUCTION; EXTRACORPOREAL OXYGENATION; FEMALE; HEART SURGERY; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; OPERATION DURATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROTHROMBIN TIME; ADVERSE EFFECTS; BIOLOGICAL MODEL; BLOOD CLOTTING; BLOOD CLOTTING TEST; BLOOD LOSS, SURGICAL; BODY HEIGHT; COMPUTER SIMULATION; DOSE CALCULATION; DRUG EFFECTS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SWEDEN; TIME FACTOR; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; BLOOD LOSS, SURGICAL; BODY HEIGHT; BODY WEIGHT; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; COMPUTER SIMULATION; DRUG DOSAGE CALCULATIONS; FEMALE; HEPARIN; HEPARIN ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; POSTOPERATIVE HEMORRHAGE; PROTAMINES; SWEDEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84939551989     PISSN: 01716425     EISSN: 14391902     Source Type: Journal    
DOI: 10.1055/s-0035-1558649     Document Type: Article

References (18)

1. Gravlee G. P. Cardiopulmonary Bypass: Principles and Practice. 3rd ed. Philadelphia, PA Lippincott: 2008
2. Finley A., Greenberg C. Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass. Anesth Analg: 2013; 116 6 1210 1222
3. Olsson P., Lagergren H., Ek S. The elimination from plasma of intravenous heparin. An experimental study on dogs and humans. Acta Med Scand: 1963; 173 619 630
4. Baker M. S., Skoyles J. R., Shajar F. M., Skinner H., Richens D., Mitchell I. M. Can lean body mass be used to reduce the dose of heparin and protamine for obese patients undergoing cardiopulmonary bypass? J Extra Corpor Technol: 2005; 37 2 153 156
5. Noui N., Zogheib E., Walczak K., et al. Anticoagulation monitoring during extracorporeal circulation with the Hepcon/HMS device. Perfusion: 2012; 27 3 214 220
6. Ni Ainle F., Preston R. J., Jenkins P. V., et al. Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation. Blood: 2009; 114 8 1658 1665
7. Khan N. U., Wayne C. K., Barker J., Strang T. The effects of protamine overdose on coagulation parameters as measured by the thrombelastograph. Eur J Anaesthesiol: 2010; 27 7 624 627
8. Cobel-Geard R. J., Hassouna H. I. Interaction of protamine sulfate with thrombin. Am J Hematol: 1983; 14 3 227 233
9. Porsche R., Brenner Z. R. Allergy to protamine sulfate. Heart Lung: 1999; 28 6 418 428
10. Butterworth J., Lin Y. A., Prielipp R. C., Bennett J., Hammon J. W., James R. L. Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass. Ann Thorac Surg: 2002; 74 5 1589 1595
11. Palmer K., Ridgway T., Al-Rawi O., Poullis M. Heparin therapy during extracorporeal circulation: deriving an optimal activated clotting time during cardiopulmonary bypass for isolated coronary artery bypass grafting. J Extra Corpor Technol: 2012; 44 3 145 150
12. Aziz K. A., Masood O., Hoschtitzky J. A., Ronald A. Does use of the Hepcon point-of-care coagulation monitor to optimise heparin and protamine dosage for cardiopulmonary bypass decrease bleeding and blood and blood product requirements in adult patients undergoing cardiac surgery? Interact Cardiovasc Thorac Surg: 2006; 5 4 469 482
13. Hofmann B., Bushnaq H., Kraus F. B., et al. Immediate effects of individualized heparin and protamine management on hemostatic activation and platelet function in adult patients undergoing cardiac surgery with tranexamic acid antifibrinolytic therapy. Perfusion: 2013; 28 5 412 418
14. Runge M., Moller C. H., Steinbrüchel D. A. Increased accuracy in heparin and protamine administration decreases bleeding: a pilot study. J Extra Corpor Technol: 2009; 41 1 10 14
15. Guffin A. V., Dunbar R. W., Kaplan J. A., Bland J. W. Jr. Successful use of a reduced dose of protamine after cardiopulmonary bypass. Anesth Analg: 1976; 55 1 110 113
16. Miyashita T., Nakajima T., Hayashi Y., Kuro M. Hemostatic effects of low-dose protamine following cardiopulmonary bypass. Am J Hematol: 2000; 64 2 112 115
17. Ferraris V. A., Brown J. R., Despotis G. J., et al. Society of Thoracic Surgeons Blood Conservation Guideline Task Force; Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion; International Consortium for Evidence Based Perfusion. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg: 2011; 91 3 944 982
18. Koch C. G., Li L., Duncan A. I., et al. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med: 2006; 34 6 1608 1616